Inefficient chemical or enzymatic coupling leads to low purity and insufficient quantities of synthetic nucleic acids. Improving yield reduces manufacturing costs and enables large-scale therapeutic production.

Inefficient peptide cyclization and poor product recovery during continuous synthesis. Improving yield and separation speed reduces manufacturing costs and material waste.